Tabula Rasa Healthcare Inc. (NASDAQ:TRHC) insider Orsula V. Knowlton sold 8,000 shares of Tabula Rasa Healthcare stock in a transaction on Wednesday, September 13th. The shares were sold at an average price of $22.10, for a total value of $176,800.00. Following the sale, the insider now directly owns 887,407 shares of the company’s stock, valued at approximately $19,611,694.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Tabula Rasa Healthcare Inc. (TRHC) traded down 2.14% during trading on Thursday, reaching $23.29. The company’s stock had a trading volume of 165,969 shares. The company’s 50 day moving average price is $22.67 and its 200 day moving average price is $17.97. Tabula Rasa Healthcare Inc. has a 52 week low of $10.39 and a 52 week high of $24.69. The company’s market cap is $402.59 million.

Tabula Rasa Healthcare (NASDAQ:TRHC) last posted its quarterly earnings data on Monday, August 7th. The company reported $0.06 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.06. Tabula Rasa Healthcare had a negative net margin of 10.27% and a negative return on equity of 9.58%. The company had revenue of $29.70 million during the quarter, compared to the consensus estimate of $27.84 million. Tabula Rasa Healthcare’s quarterly revenue was up 32.6% on a year-over-year basis. On average, equities analysts anticipate that Tabula Rasa Healthcare Inc. will post $0.39 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/09/14/tabula-rasa-healthcare-inc-trhc-insider-sells-176800-00-in-stock.html.

Several institutional investors have recently bought and sold shares of the company. California State Teachers Retirement System boosted its stake in shares of Tabula Rasa Healthcare by 60.2% during the 2nd quarter. California State Teachers Retirement System now owns 16,500 shares of the company’s stock worth $248,000 after buying an additional 6,200 shares during the last quarter. State Street Corp boosted its stake in shares of Tabula Rasa Healthcare by 38.9% during the 2nd quarter. State Street Corp now owns 69,673 shares of the company’s stock worth $1,051,000 after buying an additional 19,506 shares during the last quarter. Intrinsic Edge Capital Management LLC acquired a new position in shares of Tabula Rasa Healthcare during the 2nd quarter worth about $461,000. Hood River Capital Management LLC boosted its stake in shares of Tabula Rasa Healthcare by 7.5% during the 2nd quarter. Hood River Capital Management LLC now owns 825,225 shares of the company’s stock worth $12,420,000 after buying an additional 57,724 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Tabula Rasa Healthcare by 13.4% during the 2nd quarter. Vanguard Group Inc. now owns 236,964 shares of the company’s stock worth $3,566,000 after buying an additional 27,997 shares during the last quarter. Institutional investors own 28.85% of the company’s stock.

A number of research firms recently issued reports on TRHC. Wells Fargo & Company cut Tabula Rasa Healthcare from an “outperform” rating to a “market perform” rating and lifted their price objective for the company from $17.00 to $21.00 in a research report on Thursday, September 7th. UBS AG lifted their price objective on Tabula Rasa Healthcare from $18.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, August 30th. Piper Jaffray Companies reissued an “overweight” rating and set a $20.00 price objective (up previously from $19.00) on shares of Tabula Rasa Healthcare in a research report on Wednesday, August 9th. Chardan Capital began coverage on Tabula Rasa Healthcare in a research report on Monday, July 10th. They set a “buy” rating and a $19.50 price objective for the company. Finally, Stifel Nicolaus reissued a “buy” rating and set a $16.00 price objective on shares of Tabula Rasa Healthcare in a research report on Friday, July 14th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Tabula Rasa Healthcare currently has an average rating of “Buy” and an average target price of $19.43.

About Tabula Rasa Healthcare

Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.

Insider Buying and Selling by Quarter for Tabula Rasa Healthcare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa Healthcare Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa Healthcare Inc. and related companies with MarketBeat.com's FREE daily email newsletter.